18th December 2012 Content supplied by: Quidel Corporation
FDA Clearance for Quidel AmpliVue® Hand-Held C.difficile Assay
Quidel Corporation has received 510(k) clearance from the United States Food and Drug Administration (FDA) for the sale of Quidel's non-instrumented molecular diagnostic test -- the AmpliVue C. difficile Assay -- for the detection of toxigenic Clostridium difficile bacterial DNA.
Detection of the pathogen is achieved using a hand-held, fully contained cassette that combines isothermal Helicase Dependent Amplification (HDA) with its lateral flow detection technology.
Traditional methods for diagnosing C. difficile infections, such as glutamate dehydrogenase (GDH) or toxin antigen tests, can lack sensitivity and increase lab costs due to additional confirmation testing. In addition to significant technical expertise, cytotoxicity assays and toxigenic culture require 24-48 hours and 3-5 days, respectively, before reliable results can be obtained. The AmpliVue C. difficile Assay will now enable laboratories to offer a fast and sensitive result generated by molecular methods using actual kit components, without the need to purchase and maintain expensive capital equipment. The assay also requires no upfront nucleic acid extraction step.
'We are very pleased to receive 510(k) clearance for the first hand-held molecular device for C. difficile,' said Douglas Bryant, president and chief executive officer of Quidel Corporation. 'The AmpliVue C. difficile Assay will allow hospitals currently using traditional detection methods to employ a more sensitive, rapid molecular test, thereby providing laboratory technicians and the physicians they serve with accurate, timely, and reliable diagnosis of C. difficile infections.'
The C. difficile assay is Quidel's first assay in the hand-held AmpliVue format, and is now available for sale in the U.S. and Europe.
Date Published: 18th December 2012
Source article link: View
3M Molecular Detection Assay Salmonella
Christmas Time...Yeasts, Moulds and